REO13 Brain

• Research type

  Research Study

• Full title

  A clinical study to evaluate the biological effects of preoperative intravenous administration of wild-type reovirus (REOLYSIN®) in patients prior to surgical resection of recurrent high grade primary or metastatic brain tumours.

• IRAS ID

  97188

• Contact name

  Alan Melcher

• Eudract number

  2011-005635-10

• ISRCTN Number

  n/a

• Research summary

  Reovirus is a naturally occurring virus that is associated with only very minor respiratory and gastrointestinal symptoms in humans such as coughs colds and diarrhoea. Infection of cancer cells by this virus can inhibit the growth of the tumour and kill cancerous cells. The administration of reovirus intravenously has been tested in patients with cancer with very few side effects and some evidence of anti-cancer activity. The purpose of this study is to investigate the anti-cancer activity of reovirus and its effect on recurrent brain tumours, or tumours that have spread to the brain from elsewhere in the body. Reovirus will be administered to patients who are due to have their brain tumour surgically removed. The brain tumour will be examined for the presence of the virus after it has been surgically removed to see whether it has had any effect in killing the tumour cells. The patient??s immune response to the reovirus will also be monitored.

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  12/YH/0402

• Date of REC Opinion

  26 Sep 2012

• REC opinion

  Further Information Favourable Opinion